A new study in mice and human tissue hints at a way to keep
cancer from spreading.
Cancer cells may
suddenly "reawaken" and spread throughout the body after years of
lying dormant. Now, scientists may be closer to understanding why.
In a new study
published Monday (Dec. 13) in Nature Cancer, scientists found that in mice,
dormant cancer cells were surrounded by larger amounts of a specific type of
collagen, the main protein that makes up connective tissue, than active cancer
cells.
The team also
examined this collagen, known as type III collagen, in samples from human
patients with head and neck cancer. Patients whose cancer had spread to their
lymph nodes tended to have primary tumors with less type III collagen nearby
than patients with no cancer in their lymph nodes, suggesting that cancer with
less type III collagen might spread more easily to other parts of the body. n their mouse models,
the scientists found that the type III collagen surrounding dormant cancer
cells seems to decrease over time, and the cancer cells become active again.
The collagen changes its structure during this process, becoming less wavy and
more linear. The researchers also identified a specific process, called a
signaling pathway, through which this collagen from the tumor changes the
body’s chemistry and keeps the nearby cancer cells dormant. They discovered
that disrupting this process causes cancer cells to "reactivate."
These distinct
changes in type III collagen could be a useful marker for determining if cancer
is more likely to spread, or metastasize, said study senior author Jose Javier
Bravo-Cordero, an associate professor of medicine, hematology and medical
oncology at the Tisch Cancer Institute at Mount Sinai in New York. The researchers
also found that in mice, replacing the tumors with scaffolds made of this
collagen could prevent metastatic tumor growth, which, if it were effective in
humans, could serve as a future cancer treatment.
In the new research,
the team used mouse models of head and neck cancer and breast cancer to study
both active and dormant cancer cells. When introduced to the mice, the active
cells formed tumors and the cancer spread, while the dormant cancer cells
formed small clumps that remained in isolated areas and did not grow or spread.
Among other tools, the researchers used a specialized form of microscopy to
observe cancer cells inside live mice in real time. Bravo-Cordero compared the
method to using a security camera in a store. Looking at still images taken by
a security camera individually or out of sequence wouldn’t necessarily catch a
thief, he said, but a video recording would tell a more complete story.
"That's what
we're trying to do with the cancer cells," Bravo-Cordero told Live
Science. "We want to film them in real time so we can understand their
process and their behavior." In this way, the team spotted the differences
in collagen between the tumor types.
"If you have a
tumor that has a tendency to lose collagen expression, over time the cells that
disseminate may be more efficient in restoring growth and forming metastases
than the ones that overexpress collagen," Bravo-Cordero said.
To test whether type
III collagen could prevent cancer metastases and lessen cancer growth in mice,
the researchers introduced type III collagen into the mice in several ways,
including by injecting both cancer cells and the collagen into the animals at the
same time. The resulting tumors grew more slowly than tumors in mice injected
with only cancer cells. In a different experiment, the researchers also placed
a tiny, bioengineered scaffold loaded with type III collagen into an area where
they had removed a tumor from the mice.
Only 20% of the mice with the scaffolds had the cancer return in that area,
versus 80% in the control group.
"In that
condition, what we see is that we can prevent the recurrence of those
tumors," said Bravo-Cordero, by "forcing the cells into the dormant
state." If the same thing held true in humans, a method like this could
potentially be used as a cancer treatment, he said.
Of course, there is
no guarantee the same would hold true in humans. There’s also no guarantee that
type III collagen would have the same role for multiple types of cancer, or
even for different types of dormant cancer cells.
Just as "human
cancers are very different from one patient to the other, it's almost certainly
the case that there will be great heterogeneity in the mechanisms of
dormancy," said Dr. Lewis Chodosh, the chairman of the department of
cancer biology at the Perelman School of Medicine at the University of
Pennsylvania, who was not involved in the study. In other words, cancer cells
likely have several ways of remaining dormant, and this may only be one of
them.
Chodosh said a major
strength of the study is the many methods the researchers used to collect data,
incorporating data from mice and human samples. But a challenge of this type of
cancer research is "understanding which of the things discovered in experimental
systems are applicable to humans and in which clinical contexts," he said.
Future research will
help answer these questions, as well as others, such as how long such collagen
treatments could keep the cancer cells dormant. Still, the new research brings
us closer to understanding one of the most mysterious and deadly aspects of
cancer growth.
'This is an
understudied area in cancer biology that has critical relevance to cancer
patients," Chodosh said.
Originally published on Live Science.